Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Key Inclusion Criteria:

- Patient has pathologically (histologically or cytologically) proven diagnosis of small
cell lung cancer

- Has limited-stage disease (stage Tx, T1-T4, N0-3, M0; AJCC staging, 8th edition), and
can be safely treated with definitive radiation doses.

- Patient has not received any prior treatment for LS-SCLC.

- Patient has measurable disease as assessed according to RECIST v1.1 that is
appropriate for selection as a target lesion for repeat measurement, as determined by
local site investigator/radiology review

- ECOG Performance Status ≤ 2 assessed within 7 days before the first administration of
study intervention, and must have a life expectancy of ≥ 12 weeks.

Key Exclusion Criteria:

- Mixed small cell lung cancer histology. Note: mixed SCLC with the component of
neuroendocrine carcinoma origin is considered eligible

- Have received surgical resection for LS-SCLC

- Any patient for whom the tumor is considered resectable by surgery or stereotactic
body radiation therapy/stereotactic ablative radiotherapy should be considered
ineligible

- Is expected to require any other form of antineoplastic therapy while on study.

- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, or any other
antibody or drug specifically targeting T-cell costimulation or checkpoint pathways

Note: Other protocol-defined Inclusion/Exclusion criteria may apply